Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.

Virchows Archiv : an International Journal of Pathology
Heinz LäubliAlfred Zippelius

Abstract

Recent progress in the understanding of immune responses to cancer and how tumor cells evade immune control have led to the successful introduction of cancer immunotherapy, in particular immune checkpoint inhibitors (ICI). Treatment of cancer patients with immunotherapy such as ICIs has led to new challenges, including starting and stopping rules for immunotherapy, the management of immune-related adverse events, and logistic issues for the production of cellular therapies and viral delivery vectors. These challenges are not disease- or organ-specific and several potential biomarkers to predict response to ICI are under investigation. We installed an interdisciplinary discussion platform for managing patient-specific challenges associated with cancer immunotherapy in our institution. Here, we describe an immune tumor board for the management of cancer patients treated with immunotherapy and provide an outlook on how such a platform could be potentially used in the future to discuss rational and personalized combination therapies, and how to improve the management of side effects occurring under immunotherapy.

References

Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Apr 4, 2015·Science·Padmanee Sharma, James P Allison
Apr 4, 2015·Science·Steven A Rosenberg, Nicholas P Restifo
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Apr 11, 2015·Cancer Cell·Suzanne L TopalianDrew M Pardoll
Apr 22, 2015·The New England Journal of Medicine·Michael A PostowF Stephen Hodi
Apr 23, 2015·Journal for Immunotherapy of Cancer·Heinz LäubliAlfred Zippelius
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jul 25, 2015·Nature Reviews. Cancer·Ignacio MeleroJohn Haanen
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jan 11, 2016·Journal of Internal Medicine·S MuenstS Hoeller
Jan 15, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M MichotO Lambotte
Mar 17, 2016·Journal for Immunotherapy of Cancer·Viktor H KoelzerKirsten D Mertz
Jul 15, 2016·The New England Journal of Medicine·Matthew S DavidsUNKNOWN Leukemia and Lymphoma Society Blood Cancer Research Partnership
Jul 20, 2016·The New England Journal of Medicine·Jesse M ZaretskyAntoni Ribas
Aug 16, 2016·The Journal of Clinical Investigation·Adil I DaudMichael D Rosenblum
Nov 3, 2016·Cancer Immunology Research·Douglas B JohnsonChristine M Lovly
Oct 1, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M MenziesG V Long
Nov 3, 2016·The New England Journal of Medicine·Douglas B JohnsonJavid J Moslehi
Dec 3, 2016·Cancer Discovery·Daniel Sanghoon ShinAntoni Ribas
Dec 30, 2016·Cancer Discovery·Valsamo AnagnostouVictor E Velculescu
Jan 20, 2017·Nature·Daniel S Chen, Ira Mellman
Feb 20, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ralf GutzmerUNKNOWN German Dermatooncology Group (DeCOG)
Apr 12, 2017·Nature·Alexander C HuangE John Wherry
May 6, 2017·Nature Medicine·Carl H JuneJeffrey A Bluestone
May 13, 2017·Cell Reports·Angel Garcia-DiazAntoni Ribas
Jun 24, 2017·Journal for Immunotherapy of Cancer·Heinz LäubliFrank Stenner-Liewen
Jun 27, 2017·The Journal of Clinical Investigation·Mark AyersTerrill K McClanahan
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin
Oct 21, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Reinhard BüttnerMing-Sound Tsao

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.